Novel Cellular Immune Profiles to Predict Lung Disease Outcomes

预测肺部疾病结果的新型细胞免疫特征

• 批准号: 8259732
• 负责人: Scott M Palmer
• 金额: $ 45.27万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2013-08-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8259732
• 关键词: Adverse effects; Affect; Antigens; Autoantigens; Autoimmune Diseases; Autoimmunity; Bioinformatics; Biological Assay; Biological Markers; Blood; Blood specimen; Bronchiolitis Obliterans; Cells; Chronic; Clinical; Collagen Type V; Collection; Commit; Computing Methodologies; Delayed Hypersensitivity; Development; Diagnosis; Diagnostic; Disease; Disease Outcome; Effectiveness; Effector Cell; Fibrosis; Flow Cytometry; Future; General Population; Goals; Graft Rejection; Human; Immune; Immune response; Immune system; Immunologic Monitoring; Immunosuppression; Immunosuppressive Agents; Incidence; Individual; Instruction; Intervention; Liquid substance; Lung; Lung Inflammation; Lung Transplantation; Lung diseases; Measures; Mediating; Memory; Modeling; National Heart, Lung, and Blood Institute; Obstruction; Outcome; Pathogenesis; Pathway interactions; Patients; Pneumonia; Population; Principal Investigator; Production; Pulmonology; Qualifying; Regulatory T-Lymphocyte; Research; Research Personnel; Risk; Site; Spirometry; Statistical Methods; Stratification; Syndrome; T memory cell; T-Lymphocyte; Testing; Therapeutic Intervention; Time; Toxic effect; Transplant Recipients; Transplantation; Validation; alemtuzumab; base; cytokine; design; effective intervention; experience; high risk; improved; innovation; lung injury; meetings; novel; novel diagnostics; patient population; peripheral blood; pre-clinical; prevent; programs; response; statistics; symposium; tool

DESCRIPTION (provided by applicant): Fibrotic lung diseases are increasingly important lung conditions, with a rising incidence in the general population. Our application focuses on bronchiolitis obliterans syndrome (BOS), a fibrotic disease that occurs after human lung transplantation and is the primary reason for poor long-term survival among lung transplant recipients. Compelling evidence suggests that immune dysregulation involving regulatory T cells (Tregs), effector/memory T cells, and autoimmunity to type V collagen (Col-V) occurs in BOS. Normally hidden from the immune system, Col-V may be exposed in the setting of lung injury or inflammation and become an immune system target. Because ofthe importance of immune dysregulation and autoimmunity in the pathogenesis of BOS, the primary hypothesis to be tested is that alterations in Treg or T effector/memory populations and/or their polyfunctional cytokine response to Col-V predict the development of BOS. We will leverage the large clinical transplant population at Duke, prospectively obtained and previously banked PB samples, and the expertise of a highly experienced multi-disciplinary team of investigators. We will test this hypothesis through complementary aims that use polychromatic flow cytometry to measure T subsets in the peripheral blood (Aim 1) and their Col-V antigen specific responses (Aim 2) and apply innovative statistics and bioinformatics to identify precise cellular predictors of BOS (Aim 3). Our bioinformatics approach is designed to identify novel candidate immune biomarkers using multivariate mixture modeling and to facilitate application into clinical diagnostics using discriminative information measures that define the minimal group of markers necessary to identify predictive cellular subsets. In CADET-2, we will use these approaches to identify individual at high risk for BOS and test the idea that specific clinical interventions, such as intensification of immunosuppression, will delay or prevent its onset. As immune dysregulation appears a central theme across many chronic fibrotic lung diseases, a long-term development goal is to use the clinical, technical and bioinformatics expertise established through these proof-of-concept studies in lung transplant to bring advanced immune profiling to the forefront of clinical diagnostics in pulmonary medicine. RELEVANCE (See instructions): Although lung transplantation benefits many patients with advanced lung disease, long-term outcomes after lung transplantation are limited by progressive ainway fibrosis called bronchiolitis obliterans. Our research will identify novel immune biomarkers in the blood that can identify patients at high risk for this condition, thereby allowing for early and more effective interventions that will improve long-term transplant outcomes

描述（由申请人提供）：纤维化肺病是越来越重要的肺部疾病，在普通人群中的发病率不断上升。我们的应用集中在闭塞性细支气管炎综合征（BOS），一种发生在人类肺移植后的纤维化疾病，是肺移植受者长期生存率低的主要原因。令人信服的证据表明，免疫失调涉及调节性T细胞（T细胞），效应/记忆T细胞，和自身免疫V型胶原（Col-V）发生在BOS。Col-V通常隐藏在免疫系统之外，但在肺损伤或炎症的情况下可能会暴露出来，并成为免疫系统的目标。由于免疫失调和自身免疫在BOS发病机制中的重要性，待检验的主要假设是Treg或T效应/记忆群体和/或其对Col-V的多功能细胞因子应答的改变预测BOS的发展。我们将利用杜克的大量临床移植人群、前瞻性获得的和先前储存的PB样本以及经验丰富的多学科研究团队的专业知识。我们将通过互补的目标来测试这一假设，即使用多色流式细胞术测量外周血中的T亚群（目标1）及其Col-V抗原特异性反应（目标2），并应用创新的统计学和生物信息学来识别BOS的精确细胞预测因子（目标3）。我们的生物信息学方法被设计为使用多变量混合建模来识别新的候选免疫生物标志物，并使用定义识别预测性细胞子集所需的最小标记物组的判别信息措施来促进应用于临床诊断。在CADET-2中，我们将使用这些方法来识别BOS高风险个体，并测试特定临床干预措施（如加强免疫抑制）将延迟或预防其发作的想法。由于免疫失调似乎是许多慢性纤维化肺病的中心主题，因此长期发展目标是利用通过这些肺移植概念验证研究建立的临床，技术和生物信息学专业知识，将先进的免疫分析带到肺部医学临床诊断的最前沿。相关性（参见说明）：尽管肺移植对许多晚期肺病患者有益，但肺移植后的长期结果受到称为闭塞性细支气管炎的进行性气道纤维化的限制。我们的研究将确定血液中新的免疫生物标志物，可以识别这种疾病的高风险患者，从而允许早期和更有效的干预措施，这将改善长期移植结果